Collectively, these findings indicate that MTCH2 overexpression drives NSCLC cell growth by maintaining elevated mitochondrial activity, suggesting MTCH2 as a potential therapeutic target for NSCLC. The gene discussed is MTCH2; the disease is non-small cell lung carcinoma.